Abstract: The method of this invention is directed to a treatment of hypersomnia or insomnia that is secondary to another condition in men and women by administering to a patient a therapeutically effective amount of chromium in a pharmaceutically acceptable form, for instance in conjunction with the administration of another composition to treat the other condition, such as a standard antidepressant composition, such as a selective serotonin reuptake inhibitor composition. Chromium is administered to the patient at dosages in a preferred range of about 200 to about 500 micrograms chromium.

Abstract: The use of &agr;-lipoic acid or &agr;-dihydrolipoic acid for increasing the bioavailability of mineral salts, the use of &agr;-lipoic acid or &agr;-dihydrolipoic acid in combination with metal salts, in particular the use of metal &agr;-lipoates, metal &agr;-dihydrolipoates or metal-&agr;-lipoic acid complexes, in particular in mineral preparations or drugs and the metal &agr;-lipoates, metal &agr;-dihydrolipoates or metal-&agr;-lipoic acid complexes themselves are described.

Abstract: The invention provides a method for enhancing the water solubility of cytotoxic trans-platinum complexes. The present invention also provides a method for killing tumor cells, and a method for the treatment of tumors by the administration of a cytotoxic platinum coordination complex of the general formula SP4-2-[PtX(L)(L′)(B)]+.

Abstract: A composition for accelerating the disposal of ethanol from bodily fluid. Certain additives can accelerate the metabolic oxidation of ethanol, and others in addition act as catalysts or “pseudo” enzymes for the oxidation. Additives include the oxidant Nicotinamide Adenine Dinucleotide and a variety of other additives such as transition metal ions and complexes thereof which favor the oxidation reaction. The compositions described can act as a sobriety inducer and/or as an effective palliative for the unpleasant effects of overuse of ethanol.

Abstract: A composition comprising (a) a metal complex of a cyclic thiohydroxamic acid such as the 2:1 zinc complex of 3-hydroxy-4-methylthiazol-2(3H)-thione and (b) a salt of the metal such as zinc chloride, acetate or oxide. The presence of component (b) gives enhanced microbiological activity.

Abstract: The present invention is directed to complexes comprising iron in the ferric state and a hydroxypyrone. The present invention is also directed to methods of making such complexes and to the use of the complexes in the treatment and prevention of iron deficiency disorders including iron deficiency anaemia.

Abstract: Nutritional compositions comprising aloe vera, hydrolyzed collagen, garcinia cambogia, chromium polynicotinate, chromium picolinate, chromium cruciferate, conjugated linoleic acid, fiber and natural amino acids are disclosed. Nutritional compositions comprising aloe vera, hydrolyzed collagen, garcinia cambogia tea, fenugreek tea, coleus forskohli tea, chromium polynicotinate, chromium picolinate, chromium cruciferate, conjugated linoleic acid, fiber and natural amino acids are also disclosed. Methods for preparing and using these compositions are additionally provided.

Abstract: A method of controlling Take-all disease of plants by applying, preferably to the seed prior to planting, a fungicide of the formula 1

Abstract: Compositions comprising ferrous ion and an ascorbate have a synergistic effect on cartilage development. Therapeutic compositions comprising ferrous ion and an ascorbate are therefore useful in the treatment of osteoarthritis. The addition of a glucosamine, such as glucosamine hydrochloride, to the composition has a further enhanced effect on cartilage production. Therapeutic compositions comprising ferrous ion, an ascorbate and a glucosamine derivative are even more useful in the treatment of osteoarthritis.

Abstract: The present invention comprises a number of nutritional supplements, or agents and/or formulas. A first nutritional formula is designed for eliminating the cravings for consuming calories, for regulating appetite, and for countering the feeling(s) of weakness and tiredness that may encourage and or drive a person to eat when their body does not require nutritional sustenance. This first nutritional supplement is formulated to be used alone and/or selectively combined with a second nutritional agent which is a thermogenic formulated fat burning agent. This second thermogenic agent is designed to enhance fat burning. The second thermogenic agent can also be used alone. A third nutritional agent is formulated for minimizing the tendency to store fat. The third nutritional agent can also be used alone. Its effect is enhanced by use with either one or both of the other two agents.

Abstract: The invention relates to novel targeting drug agents that are targeted for entry into the mitochondria. More specifically, the agents are cisplatin derivatives called mitoplatins which are useful as anti-tumor agents. Mitoplatins are named for their targeting to the mitochondrial DNA via the carnitine-acylcarnitine translocase system. The invention also relates to methods of synthesizing mitoplatins, compositions of matter containing mitoplatins and methods of using the mitoplatins.

Abstract: Qualitative and quantitative electrochemiluminescent assays for analytes of interest present in multicomponent liquids are provided. These methods comprise contacting a sample with a reagent labeled with an electrochemiluminescent chemical moiety and capable of combining with the analyte of interest, exposing the resulting sample to electrochemical energy and detecting electromagnetic radiation emitted by the electrochemiluminescent chemical moiety.

Abstract: Compositions comprising chromic tripicolinate or chromic polynicotinate in combination with at least one of a cyclooxygenase inhibitor, an acid, a mucolytic and a salicin-containing herb. The compositions are useful for supplementing dietary chromium, lowering blood glucose levels, lowering serum lipid levels and increasing lean body mass.

Abstract: The present invention provides methods and compositions comprising one or more zinc ionophores for protecting tissue from the harmful effects of apoptosis in patients in need thereof. Concentrations of zinc-pyrithione and diethyldithiocarbamate in the picomolar to nanomolar range have a strong protective effect against apoptosis.

Abstract: Methods for performing ring-opening cross-metathesis reactions on solid support are disclosed. Substituted cyclic compounds, libraries of the compounds, and methods of using the compounds to treat bacterial infections are also disclosed.

Abstract: Disclosed herein are anti-inflammatory and anti-ulcer copper coordination compounds and a process for using them in the treatment of arthritis and gastrointestinal ulcers in animal bodies. The copper coordination compounds utilized are the reaction products of copper salts with: 1. aromatic carboxylic acids or their alkaline earth salts; 2. heterocyclic carboxylic acids or their alkaline earth salts; 3. amino acids or their alkaline earth salts; 4. amines; and 5. suitably substituted steroids. The process disclosed comprises administering to experimental animals, orally or parentrally (subcutaneously), in controlled dosages, the aforementioned copper coordination compounds for the treatment of inflammation (i.e., arthritis) and ulcers of the gastrointestinal tract.

Abstract: Compositions and methods for treating gastrointestinal symptoms and gastrointestinal microbes are provided. In accordance with the method, a dietary metal and a dietary ligand are administered, wherein the dietary metal is zinc, copper, cobalt, manganese or iron and the dietary ligand is ascorbate, aspartate, citrate, histidine, malate, maltol, gluconate, glutamate, glutamine, succinate, tartrate, or a combination thereof.

Abstract: The invention relates to an oral care composition with antiplaque agents. The antiplaque agents are complexes of divalent copper, zinc, iron or tin, or trivalent iron with a specific class of cyclic &agr;-hydroxyketones. A typical example is the copper (II)-ethylmaltol complex. These complexes are more active antiplaque agents that e.g. copper-hinokitiol complexes.

Abstract: Pharmaceutical compositions of vanadium biguanide complexes, and methods of use, are provided for the treatment of hyperglycemia and related disorders, e.g. hypertension, obesity, and lipid disturbances. The pharmaceutically active complexes of the invention comprise a biguanide chelant, preferably a 1-substituted biguanide chelant, capable of chelating vanadium to form a six-membered unsaturated vanadium-containing ring. The vanadium of the complex is coordinated with oxygen, sulphur or nitrogen, particularly oxygen coordinated. The complexes are formulated with a physiologically acceptable carrier. In a preferred embodiment, the complexes are formulated for oral administration.

Abstract: New pharmaceutical compositions and pharmaceutical compositions comprising metal complexes have activity against diseases caused by or related to overproduction or localised high concentration of nitric oxide in the body.

Abstract: A method for inhibiting VEGF stimulated endothelial cell growth, such as associated with neoplasia, and VEGF stimulated capillary permeability, such as associated with pulmonary edema are disclosed, particularly using the &bgr;-isozyme selective PKC inhibitor, (S)-3,4-[N,N′-1,1′-((2″-ethoxy)-3′″(O)-4′″-(N,N-dimethylamino)-butane)-bis-(3,3′-indolyl)]-1(H)-pyrrole-2,5-dionehydrochloridesalt.

Abstract: Organic complexes of vanadium are provided, having the general structure VL3, where V is vanadium(III) and L is a monoprotic bidentate ligand that forms a five-membered, unsaturated vanadium containing ring, having vanadium coordinating oxygen or sulfur ring heteroatoms, and where the vanadium containing ring is fused to a six-membered heterocyclic ring. Preferably L is a hydroxypyrone or a hydroxypyridinone. The complexes have a number of uses, including the treatment of elevated blood glucose and related disorders, treatment of proliferative disorders, etc.

Abstract: Novel triazolinethione-phosphoric acid derivatives of the formula in which R1, R2, R3 and Q are each as defined in the description and their metal salt complexes, a process for preparing the novel substances and their use as microbicides in crop protection and in the protection of materials are described.

Abstract: This invention relates to the use of compounds having the general structure: wherein: Z1 and Z2 each independently represent an arene nucleus, which has from 5 to 14 ring atoms; G1 and G2 each independently represent a metal ligating group; R represents a hydrogen atom, a halogen atom, an alkyl group, an acylamino group, an alkoxy group, a sulfonamido group, an aryl group, a thiol group, an alkylthio group, an arylthio group, an alkylamino group, an arylamino group, an amino group, an alkoxycarbonyl group, an acyloxy group, a nitro group, a cyano group, an alkylsulfonyl group, an arylsulfonyl group, an alkylsulfoxyl group, an arylsulfoxyl group, an aryloxyl group, a hydroxyl group, a thioamido group, a carbamoyl group, a suffamoyl group, a formyl group, an acyl group, a ureido group, an aryloxycarbonyl group, a silyl group, or a sulfoalkoxy group; L1 represents a nitrogen heterocycle; L2 represents a monodentate or polydentate (e.g.

Abstract: The present invention provides a method for the treatment of diseases by the decomposition of peroxynitrite, preferably decomposition to benign products, comprising the use of a complex which is a selected ligand structure providing a complexed metal such as Mn, Fe, Ni and V transition metals. The method of use, as well as novel pharmaceutical compositions therefor, are for the treatment of diseases advantageously affected by decomposition of peroxynitrite ed at a rate over the natural background rate of decay of peroxynitrite in humans suffering from the disease which comprises administration of an amount of a complex, in dosage unit form, which is effective for such acceleration of the decomposition of peroxynitrite .

Abstract: The invention provides, as contrast signal generators in MR imaging of the digestive tract, paramagnetic metal chelates of novel acrylic compounds of formula C(R1R2)═CR3—CO—Z—Z (1) and/or C(R1R2)═CR3—CO—Z—Z—Z—CO—CR3═C(R1R2) (2) in monomer, oligomer, homopolymer and copolymer forms, in which the R1, R2 and R3 represent H or saturated or unsaturated C1-10 aliphatic radicals optionally substituted by one or more OH groups; Z is a covalent bond or a linker spacer and A is a moiety capable of fixing a paramagnetic metal by chelation. Compounds of type (1) useful in the present invention are, for instance the polyalkylene-aminopolycarboxylic acids such as NTA, EDTA, DTPA, DOTA and like structures, possibly involving additional substituents; an example is the compound BOPTA which is a DTPA derivative carrying a benzyloxypropyl group.

Abstract: Disclosed are compositions comprising 1) taxol, taxotere, or derivatives thereof and 2) a platinum coordination complex such as cisplatin, the compositions exhibiting therapeutic synergy.

Abstract: Organovanadium complexes, and more specifically hydroxyoxovanadium(V), &mgr;-oxo dimeric oxovanadium(V) and cis-dioxovanadium(V) complexes, are provided. The complexes may be formulated into a pharmaceutical composition. The complexes and/or compositions may be used in the treatment of a variety of disease states, including use as anti-proliferative and/or anti-metastatic agents and/or to treat drug resistant tumors and/or to methods of reducing the ability of tumors to metastasize and/or for the treatment of diabetes, arthritis, multiple sclerosis, diseases involving passageways of the body, and autoimmune diseases including but not limited to psoriasis and lupus.

Abstract: Magnesium (−)hydroxycitrate, preparation process, dietary and therapeutic uses particularly in the cardiovascular field, and compositions in particular pharmaceutical containing it.

Abstract: The present invention relates to compounds which are effective as catalysts for dismutating superoxide and, more particularly, the manganese or iron complexes of substituted, unsaturated heterocyclic pentaazacyclopentadecane ligands which catalytically dismutate superoxide.

Abstract: The invention provides compositions and methods for treatment of narcolepsy or isolated cataplexy. Such methods entail administering a therapeutically effective regime of at least one immunosuppressive agent. The methods are particularly useful for prophylactic and therapeutic treatment of narcolepsy or isolated cataplexy.

Abstract: The present invention is directed to low molecular weight mimics of superoxide dismutase (SOD) represented by the formula: wherein R, R′, R1, R′1, R2, R′2, R3, R′3, R4, R′4, R5, R′5, R6, R′6, R7, R′7, R8, R′8, R9, R′10, R10 and R′10, X, Y, Z and n are as defined herein, useful as therapeutic agents for inflammatory disease states and disorders, ischemic/reperfusion injury, myocardial infarction, stroke, atherosclerosis, and all other conditions of oxidant-induced tissue damage or injury.

Abstract: Novel dietary complexes for gastrointestinal symptoms and gastrointestinal microbes are provided. They comprise a dietary metal and a dietary ligand wherein the dietary metal is selected from zinc, copper, cobalt, manganese and iron and the dietary ligand is lawsone or tropolone.

Abstract: Novel organic arsenic compounds are described as cytotoxic agents with potent anti-tumor activity against cancer cells and particularly, with regard to human leukemic cells and breast cancer cells.

Abstract: Chelates of the compounds of formula I in which R is a hydrophilic group containing 3 or 4 successive phenyl rings and m is 1 or 2, with metal ions, for use in diagnostic imaging.

Abstract: Synthetic low molecular weight catalysts for the dismutation of superoxide are potent analgesics that are effective in elevating the pain threshold in hyperalgesic conditions such as arthritis, and also operate to prevent or reverse tolerance to opioid analgesics.

Abstract: The invention relates to agents for treating and preventing stomatitis, comprising an L-carnosine zinc salt or L-carnosine-zinc complex, or such a compound and sodium alginate. The agents are excellent in therapeutic and preventive effects on stomatitis and particularly exhibit marked effects on stomatitis caused by chemotherapy or radiotherapy for cancer.

Abstract: A method for imaging mammalian tissue utilizing a non-ionic complex of a paramagnetic ion of lanthanide element and a macrocyclic chelating agent.

Abstract: The present invention provides the composition for novel triazolyl disulphides, the acid addition salts and metal salt complexes of the triazolyl disulphides, a process for their preparation, and a method for their use as microbicides.

Abstract: The invention relates to new porphyrin complex compounds, pharmaceutical agents that contain the latter, and the use of porphyrin complexes for the production of agents for photodynamic therapy and MRI diagnosis.

Abstract: The present invention relates to metallated or unmetallated porphyrin derivatives which have varying amphiphilic properties and which may be bonded to polymers, and to processes of their preparation. The present invention further relates to photosensitizers comprising said porphyrin derivatives, and to the use of said photosensitizers for the catalytic formation of singlet oxygen.

Abstract: Disclosed are pharmaceutical compositions that comprise gallium complexes of 3-hydroxy-4-pyrones. These compositions provide enhanced gallium bioavailability particularly when orally administered as compared to the gallium bioavailability achieved by use of pharmaceutical compositions containing gallium salts. Compositions included in this invention are useful in providing gallium to humans and other mammals for a wide variety of medical and veterinary applications, including the treatment, prevention, or diagnosis of hypercalcemia, certain cancers, certain disorders of calcium homeostasis, and certain bone diseases including osteoporosis, osteopenia, and Paget's disease.

Abstract: The present invention has identified compounds with extended aromatic chromophores that bind the G-quadruplex formed by the folding of single-stranded human telomeric DNA. These compounds have been shown to be effective telomerase inhibitors and are contemplated to be useful in developing cancer treatments. A model of cationic porphyrin interaction with quadruplex DNA by intercalation has been established and in combination with structure activity relations has provided novel porphyrin compounds that exhibit discrimination between binding duplex and quadruplex DNA and show improved activity against telomerase.

Abstract: The invention relates to new compounds that are suitable as contrast media especially for infarction and necrosis imaging, process for their production and pharmaceutical agents that contain these compounds.

Abstract: Cascade polymers, containing complex-forming ligands, optionally at least five ions of an element of atomic numbers 21-29, 39, 42, 44 or 57-83, as well as, if desired, cations of inorganic and/or organic bases, amino acids or amino acid amides, are valuable complexing compounds and complexes for diagnostics and therapy.

Abstract: The subject invention encompasses methods for prevention and treatment of a human or lower animal subject having a gastrointestinal disorder caused or mediated by one or more intestinal helminths comprising administering to the subject bismuth and one or more antimicrobials. The subject invention also encompasses compositions comprising bismuth and one or more antimicrobials for the prevention and treatment of a human or lower animal subject having a gastrointestinal disorder caused or mediated by one or more intestinal helminths.

Abstract: The subjects of this invention are pharmaceutical compositions that comprise gallium complexes of 3-hydroxy-4-pyrones. The compositions have been developed to provide pharmaceutically acceptable gallium bioavailability together with low toxicity, particularly for oral administration. Compositions included in this invention should be useful in providing gallium to humans and other animals for a wide variety of medical and veterinary applications, including the treatment, prevention, or diagnosis of certain bone diseases, certain cancers, and certain disorders of calcium homeostasis.

Abstract: The invention provides antioxidant salen-metal complexes, compositions of such antioxidant salen-metal complexes having superoxide activity, catalase activity, and/or peroxidase activity, compositions of salen-metal complexes in a form suitable for pharmaceutical administration to treat or prevent a disease associated with cell or tissue damage produced by free radicals such as superoxide, and cosmetic and free radical quenching formulations of salen metal compounds.

Abstract: The current invention discloses useful amidino derivative useful as nitric oxide synthase inhibitors.

Abstract: Pharmaceutical compositions containing an iron complex of 3-hydroxy-4-pyrone or of a 3-hydroxy-4-pyrone in which one or more of the hydrogen atoms attached to ring carbon atoms are replaced by an aliphatic hydrocarbon group of 1 to 6 carbon atoms, are of value for the treatment of iron deficiency anaemia.